Role of poly (ADP-ribose)-polymerase and its signaling pathway with renin-angiotensin aldosterone system in renal diseases

References

• Mukhopadhyay P, Rajesh M, Cao Z, et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 2013. (Epub ahead of print)
   Google Scholar
• Sakogawa K, Aoki Y, Misumi K, et al. Involvement of homologous recombination in the synergism between cisplatin and poly(ADP-ribose) polymerase inhibition. Cancer Sci 2013. (Epub ahead of print)
   Google Scholar
• McDonald MC, Mota-Filipe H, Wright JA, et al. Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol 2000;130:843–50
   Google Scholar
• Petrilli V, Herceg Z, Hassa PO, et al. Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest 2004;114:1072–81
   Google Scholar
• Nishizawa K, Yanagida S, Yamagishi T, et al. Continuous inhibition of poly(ADP-ribose) polymerase does not reduce reperfusion injury in isolated rat heart. J Cardiovasc Pharmacol 2013;62:99–105
   Google Scholar
• Ji L, Cai X, Zhang L, et al. Association between polymorphisms in the renin-angiotensin-aldosterone system genes and essential hypertension in the han Chinese population. PLoS One 2013;8:e72701
   Google Scholar
• Reinhold SW, Kruger B, Barner C, et al. Nephron-specific expression of components of the renin-angiotensin-aldosterone system in the mouse kidney. J Renin Angiotensin Aldosterone Syst 2012;13:46–55
   Google Scholar
• Durante A, Peretto G, Laricchia A, et al. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des 2012;18:981–1004
   PubMed Web of Science ®Google Scholar
• Trost Rupnik A, Pajek J, Gucek A, et al. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients. Ther Apher Dial 2013;17:425–30
   Google Scholar
• Tylicki L, Lizakowski S, Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. J Nephrol 2012;25:900–10
   Google Scholar
• Martin DR, Lewington AJ, Hammerman MR, Padanilam BJ. Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am J Physiol Regul Integr Comp Physiol 2000;279:R1834–40
   PubMed Web of Science ®Google Scholar
• Darmon D, Goldfarb M, Shina A, Rosen S, Heyman SN. Effect of poly(ADP-ribose) polymerase inhibition on outer medullary hypoxic damage. Nephron Physiol 2003;95:1–9
   Google Scholar
• Stone DH, Al-Badawi H, Conrad MF, et al. PJ34, a poly-ADP-ribose polymerase inhibitor, modulates renal injury after thoracic aortic ischemia/reperfusion. Surgery 2005;138:368–74
   Google Scholar
• Stone DH, Albadawi H, Conrad MF, et al. PJ34, a poly-ADP-ribose polymerase inhibitor, modulates visceral mitochondrial activity and CD14 expression following thoracic aortic ischemia-reperfusion. Am J Surg 2009;198:250–5
   Google Scholar
• Black JH, Casey PJ, Albadawi H, Cambria RP, Watkins MT. Poly adenosine diphosphate-ribose polymerase inhibitor PJ34 abolishes systemic proinflammatory responses to thoracic aortic ischemia and reperfusion. J Am Coll Surg 2006;203:44–53
   PubMed Web of Science ®Google Scholar
• Zheng J, Devalaraja-Narashimha K, Singaravelu K, Padanilam BJ. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am J Physiol Renal Physiol 2005;288:F387–98
   PubMed Web of Science ®Google Scholar
• Mangino MJ, Ametani M, Szabo C, Southard JH. Poly(ADP-ribose) polymerase and renal hypothermic preservation injury. Am J Physiol Renal Physiol 2004;286:F838–47
   Google Scholar
• Tasatargil A, Aksoy NH, Dalaklioglu S, Sadan G. Poly (ADP-ribose) polymerase as a potential target for the treatment of acute renal injury caused by lipopolysaccharide. Ren Fail 2008;30:115–20
   Web of Science ®Google Scholar
• Okada H, Inoue T, Kikuta T, et al. Poly(ADP-ribose) polymerase-1 enhances transcription of the profibrotic CCN2 gene. J Am Soc Nephrol 2008;19:933–42
   Google Scholar
• Kim J, Padanilam BJ. Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Renal Physiol 2011;301:F450–9
   PubMed Web of Science ®Google Scholar
• Jog NR, Dinnall JA, Gallucci S, Madaio MP, Caricchio R. Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J Immunol 2009;182:7297–306
   PubMed Web of Science ®Google Scholar
• Shino Y, Itoh Y, Kubota T, Yano T, Sendo T, Oishi R. Role of poly(ADP-ribose)polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic Biol Med 2003;35:966–77
   PubMed Web of Science ®Google Scholar
• Abraham P, Rabi S. Aminoguanidine, a selective nitric oxide synthase inhibitor, attenuates cyclophosphamide-induced renal damage by inhibiting protein nitration and poly(ADP-Ribose) polymerase activation. Chemotherapy 2011;57:327–34
   PubMed Web of Science ®Google Scholar
• Yam-Canul P, Chirino YI, Sanchez-Gonzalez DJ, et al. PJ34, a poly adenosine diphosphate-ribose polymerase inhibitor, attenuates chromate-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2008;102:483–8
   Google Scholar
• Dalaklioglu S, Tekcan M, Gungor NE, et al. Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury. Toxicol Lett 2010;192:91–6
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Horvath B, Kechrid M, et al. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51:1774–88
   PubMed Web of Science ®Google Scholar
• Kim J, Long KE, Tang K, Padanilam BJ. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 2012;82:193–203
   PubMed Web of Science ®Google Scholar
• Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003;17:1514–16
   Google Scholar
• Drel VR, Pacher P, Stevens MJ, Obrosova IG. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. Free Radic Biol Med 2006;40:1454–65
   Google Scholar
• Szabo C, Biser A, Benko R, Bottinger E, Susztak K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 2006;55:3004–12
   PubMed Web of Science ®Google Scholar
• Chiu J, Xu BY, Chen S, Feng B, Chakrabarti S. Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications. Can J Physiol Pharmacol 2008;86:365–72
   PubMed Web of Science ®Google Scholar
• Drel VR, Xu W, Zhang J, et al. Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. Endocrinology 2009;150:5273–83
   PubMed Web of Science ®Google Scholar
• Shevalye H, Maksimchyk Y, Watcho P, Obrosova IG. Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. Biochim Biophys Acta 2010;1802:1020–7
   Google Scholar
• Shevalye H, Stavniichuk R, Xu W, et al. Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem Pharmacol 2010;79:1007–14
   Google Scholar
• O'Valle F, Benitez MC, Gomez-Morales M, et al. Correlation of morphological findings with functional reserve in the aging donor: role of the poly (ADP-ribose) polymerase. Transplant Proc 2004;36:733–5
   PubMed Web of Science ®Google Scholar
• O'Valle F, Benitez MC, Gomez-Morales M, et al. Role of poly-(ADP-ribose) polymerase in transplant acute tubular necrosis and its relationship with delayed renal function. Transplant Proc 2005;37:1421–3
   Google Scholar
• O'Valle F, Benitez MC, Gomez-Morales M, et al. Role of poly (ADP-ribose) polymerase in kidney transplant and its relationship with delayed renal function: multivariate analysis. Transplant Proc 2005;37:3684–7
   Google Scholar
• O'Valle F, Gomez-Morales M, Del Moral RM, et al. Poly(ADP-ribose) polymerase expression in kidney transplantation: from alfa (alpha) to Omega (Omega). Transplant Proc 2007;39:2099–101
   Google Scholar
• O'Valle F, Del Moral RG, Benitez Mdel C, et al. Poly[ADP-ribose] polymerase-1 expression is related to cold ischemia, acute tubular necrosis, and delayed renal function in kidney transplantation. PLoS One 2009;4:e7138
   Google Scholar
• Zhu H, Jiang Z, Lei P, Huang W, Yu X. Poly(ADP-ribose) polymerase-1 mediates angiotensin II-induced expression of plasminogen activator inhibitor-1 and fibronectin in rat mesangial cells. Kidney Blood Press Res 2011;34:320–7
   Google Scholar
• Zhou TB, Wu WF, Qin YH, Yin SS. Association of all-trans retinoic acid treatment with the renin-angiotensin aldosterone system expression in glomerulosclerosis rats. J Renin Angiotensin Aldosterone Syst 2012. (Epub ahead of print)
   Google Scholar
• Yoshida S, Ishizawa K, Ayuzawa N, et al. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading. Clin Exp Nephrol 2013. (Epub ahead of print)
   Google Scholar
• Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L. Effect of renin-angiotensin system blockade on soluble klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clin J Am Soc Nephrol 2013;8:1899--905
   Google Scholar
• Su SL, Lu KC, Lin YF, et al. Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population. J Renin Angiotensin Aldosterone Syst 2012;13:148–54
   PubMed Web of Science ®Google Scholar
• Zhou TB, Drummen GP, Jiang ZP, et al. Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases. J Recept Signal Transduct Res 2013. (Epub ahead of print)
   Google Scholar
• Zhou TB. Signaling pathways of PAX2 and its role in renal interstitial fibrosis and glomerulosclerosis. J Recept Signal Transduct Res 2012;32:298–303
   PubMed Web of Science ®Google Scholar
• Zhou TB. Signaling pathways of apoE and its role of gene expression in glomerulus diseases. J Recept Signal Transduct Res 2013;33:73–8
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH. The signaling pathways of LMX1B and its role in glomerulosclerosis. J Recept Signal Transduct Res 2012;32:285–9
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH. The potential mechanism for the different expressions of gelatinases induced by all-trans retinoic acid in different cells. J Recept Signal Transduct Res 2012;32:129–33
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH. Signaling pathways of prohibitin and its role in diseases. J Recept Signal Transduct Res 2013;33:28–36
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Zhang F, et al. Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats. Int J Cardiol 2013;167:2285–93
   Google Scholar
• Huang D, Wang Y, Yang C, Liao Y, Huang K. Angiotensin II promotes poly(ADP-ribosyl)ation of c-Jun/c-Fos in cardiac fibroblasts. J Mol Cell Cardiol 2009;46:25–32
   PubMedGoogle Scholar
• Chan LY, Leung JC, Tang SC, Choy CB, Lai KN. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 2005;16:2306–17
   PubMed Web of Science ®Google Scholar
• Szabo C, Pacher P, Zsengeller Z, et al. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 2004;10:28–35
   PubMed Web of Science ®Google Scholar
• Asmussen S, Bartha E, Olah G, et al. The Angiotensin-converting enzyme inhibitor captopril inhibits poly(adp-ribose) polymerase activation and exerts beneficial effects in an ovine model of burn and smoke injury. Shock 2011;36:402–9
   PubMed Web of Science ®Google Scholar
• Shrikhande G, Khaodhiar L, Scali S, et al. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J Vasc Surg 2006;43:760–70; discussion 70–71
   PubMed Web of Science ®Google Scholar
• Shenoy UV, Richards EM, Huang XC, Sumners C. Angiotensin II type 2 receptor-mediated apoptosis of cultured neurons from newborn rat brain. Endocrinology 1999;140:500–9
   Google Scholar
• Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, Gupta MP. Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2006;291:H1545–53
   PubMed Web of Science ®Google Scholar
• Fukamizu A, Takahashi S, Murakami K. Expression of the human angiotensinogen gene in human cell lines. J Cardiovasc Pharmacol 1990;16:S11–13
   PubMedGoogle Scholar
• Menk M, von Haefen C, Funke-Kaiser H, et al. Ethanol-induced downregulation of the angiotensin AT2 receptor in murine fibroblasts is mediated by PARP-1. Alcohol 2010;44:495–506
   PubMed Web of Science ®Google Scholar